Anti-Acinetobacter baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model

期刊论文
出版模式：

开放获取
发表日期：

2024年2月10日

查看全文

Eilnaz Basardeh,
Somayeh Piri-Gavgani,
Hamid Reza Moradi,
Masoumeh Azizi,
Parastoo Mirzabeigi,
Farzaneh Nazari,
Mostafa Ghanei,
Fereidoun Mahboudi,
Fatemeh Rahimi-Jamnani

摘要

Background

The emergence of carbapenem-resistant and extensively drug-resistant (XDR) Acinetobacter baumannii as well as inadequate effective antibiotics calls for an urgent effort to find new antibacterial agents. The therapeutic efficacy of two human scFvs, EB211 and EB279, showing growth inhibitory activity against A. baumannii in vitro, was investigated in immunocompromised mice with A. baumannii pneumonia.

Results

The data revealed that infected mice treated with EB211, EB279, and a combination of the two scFvs showed better survival, reduced bacterial load in the lungs, and no marked pathological abnormalities in the kidneys, liver, and lungs when compared to the control groups receiving normal saline or an irrelevant scFv.

Conclusions

The results from this study suggest that the scFvs with direct growth inhibitory activity could offer promising results in the treatment of pneumonia caused by XDR A. baumannii.